Immunotherapy and surgery for stage 3 lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new approach: giving an immunotherapy drug (tislelizumab) plus chemotherapy before surgery or radiation for advanced lung cancer that has spread to chest lymph nodes. The goal is to shrink the cancer first, then remove or treat it, to improve chances of long-term control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lung cancer called non-small cell lung cancer that has spread to lymph nodes in the center of the chest (N3).
- You must be generally well enough to carry out daily activities (ECOG score 0 or 1).
- You must not have had any prior lung cancer treatment (like chemotherapy, radiation, or surgery).
- You must not have certain gene changes in your tumor that already have targeted treatments (like EGFR or ALK).
- You must not have an active autoimmune disease or a history of one that could flare up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests combining the drug tislelizumab with chemotherapy for people with stage III non-small cell lung cancer that hasn't been treated yet. It aims to see if this combination can shrink or control the cancer better.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.